Table 4.
Clinicopathological characteristics and associations with PIK3CA and TP53 in 275 breast cancer patients.
| Total (275) |
PIK3CA co-mutation (82) |
TP53 co mutation (121) |
PIK3CA + TP53 (39) |
||||
|---|---|---|---|---|---|---|---|
| Characteristic | Number | Mutant (%) | WT | Mutant (%) | WT | Mutant (%) | WT |
| Age at diagnosis | |||||||
| <40 | 65 (23.6) | 11 (13.4%) | 54 (28.0%) | 29 (23.9%) | 36 (23.4%) | 4 (10.8%) | 61 (25.8%) |
| 40–65 | 185 (67.3) | 63 (76.8%) | 122 (63.2) | 84 (69.4%) | 101 (65.6%) | 31(83.7%) | 154 (65.3%) |
| >65 | 25 (9%) | 8 (9.8%) | 17 (8.8) | 8 (6.6%) | 17 (11.0%) | 2 (5.4%) | 23 (9.7%) |
| Hormonal status | |||||||
| HR (+) | 147(60.7%) | 56 (38%) | 91 (62%) | 41 (33.9%) | 95 (61.7%) | 28 (71.8%) | 108 (45.8%) |
| HR (+) Her2 (+) | 29 (19%) | 11 (38%) | 18(62%) | 9 (7.4%) | 12 (7.8%) | 4 (10.3%) | 17 (7.2) |
| HR (+) Her2(−) | 118 (83%) | 45 (38%) | 73 (62%) | 32 (26.4%) | 83 (53.9%) | 20 (51.3%) | 95 (40.3) |
| HR (−)Her2 (+) | 22 (11%) | 4 (18%) | 18 (82%) | 16 (13.2%) | 13 (8.4%) | 2 (5.1%) | 27 (11.4%) |
| HR (−)Her2 (−) | 73 (30%) | 13 (18%) | 60 (82%) | 51 (42.1%) | 25 (16.2%) | 8 (20.5%) | 68 (28.8%) |
| HR Her2 (unknown) | 33 (13.6) | 25 (13.0%) | 9 (11%) | 13 (10.7%) | 21 (13.6%) | 5 (12.8%) | 29 (12.3%) |
| Ki 67 expression | |||||||
| <15 | 25 (9.1%) | 6 (24%) | 19 (9.8) | 4 (16%) | 21 (13.6%) | 3 (12%) | 22 (9.3%) |
| >15 | 162 (58.9%) | 54 (33%) | 108 (56.0%) | 75 (46.3%) | 87 (56.5%) | 23 (14.2%) | 139 (58.9%) |
| Unknown | 88 (32.0%) | 22 (25%) | 66 (34.2%) | 42 (47.8%) | 46 (29.9%) | 13 (14.8%) | 75 (31.8%) |
| Age at diagnosis | |||||||
| <40 | 65 (23.6) | 11 (13.4%) | 54 (28.0%) | 29 (23.9%) | 36 (23.4%) | 4 (10.8%) | 61 (25.8%) |
| 40–65 | 185 (67.3) | 63 (76.8%) | 122 (63.2) | 84 (69.4%) | 101 (65.6%) | 31(83.7%) | 154 (65.3%) |
| >65 | 25 (9%) | 8 (9.8%) | 17 (8.8) | 8 (6.6%) | 17 (11.0%) | 2 (5.4%) | 23 (9.7%) |
| Hormonal status | |||||||
| HR (+) | 147(60.7%) | 56 (38%) | 91 (62%) | 41 (33.9%) | 95 (61.7%) | 28 (71.8%) | 108 (45.8%) |
| HR (+) Her2 (+) | 29 (19%) | 11 (38%) | 18(62%) | 9 (7.4%) | 12 (7.8%) | 4 (10.3%) | 17 (7.2) |
| HR (+) Her2(−) | 118 (83%) | 45 (38%) | 73 (62%) | 32 (26.4%) | 83 (53.9%) | 20 (51.3%) | 95 (40.3) |
| HR (−)Her2 (+) | 22 (11%) | 4 (18%) | 18 (82%) | 16 (13.2%) | 13 (8.4%) | 2 (5.1%) | 27 (11.4%) |
| HR (−)Her2 (−) | 73 (30%) | 13 (18%) | 60 (82%) | 51 (42.1%) | 25 (16.2%) | 8 (20.5%) | 68 (28.8%) |
| HR Her2 (unknown) | 33 (13.6) | 25 (13.0%) | 9 (11%) | 13 (10.7%) | 21 (13.6%) | 5 (12.8%) | 29 (12.3%) |
| Ki 6 7 expression | |||||||
| <15 | 25 (9.1%) | 6 (24%) | 19 (9.8) | 4 (16%) | 21 (13.6%) | 3 (12%) | 22 (9.3%) |
| >15 | 162 (58.9%) | 54 (33%) | 108 (56.0%) | 75 (46.3%) | 87 (56.5%) | 23 (14.2%) | 139 (58.9%) |
| Unknown | 88 (32.0%) | 22 (25%) | 66 (34.2%) | 42 (47.8%) | 46 (29.9%) | 13 (14.8%) | 75 (31.8%) |